Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial

IMPORTANCE: Individuals living with schizophrenia are affected by cardiometabolic, endocrine, and motor adverse effects of current antipsychotic medications. Lumateperone is a serotonin, dopamine, and glutamate modulator with the potential to treat schizophrenia with few adverse effects. OBJECTIVE:...

Descripción completa

Detalles Bibliográficos
Autores principales: Correll, Christoph U., Davis, Robert E., Weingart, Michal, Saillard, Jelena, O’Gorman, Cedric, Kane, John M., Lieberman, Jeffrey A., Tamminga, Carol A., Mates, Sharon, Vanover, Kimberly E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990963/
https://www.ncbi.nlm.nih.gov/pubmed/31913424
http://dx.doi.org/10.1001/jamapsychiatry.2019.4379

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990963/
https://www.ncbi.nlm.nih.gov/pubmed/31913424
http://dx.doi.org/10.1001/jamapsychiatry.2019.4379

Ejemplares similares